Implantable drug-loaded device

Abstract

The invention relates to an implantable drug-carrying device, which comprises a zinc-containing substrate and an active drug layer attached to the zinc-containing substrate. In the zinc-containing substrate per unit area, the content of the active drug is ρ (μg mm ‑2 ), the zinc content of the zinc-containing substrate per unit area corroded per unit time in 8.3vol.% superior grade pure acetic acid aqueous solution is p (μg·mm ‑2 min ‑1 ), the value of ρ and the value of p satisfy the following relationship: 0.1≤15p+ρ≤3.5; wherein, 0.005≤p≤0.14. The zinc release rate of the implantable drug-loaded device matches the content of the active drug, so that after implantation in the body, the synergistic effect of the zinc and the drug can effectively inhibit the proliferation of smooth muscle cells without killing cells and causing tissue necrosis.

Description

technical field [0001] The invention relates to the field of interventional medical devices, in particular to an implantable drug-carrying device. Background technique [0002] At present, the commonly used treatment methods for lumen stenosis are interventional procedures such as percutaneous transluminal angioplasty, that is, the narrowed lumen is expanded to a normal size by implantable devices. Therefore, local damage will occur at the implantation site. During the critical period of tissue repair, the proliferation of smooth muscle cells is the most serious. When the luminal tissue passes through the critical period of repair, smooth muscle proliferation gradually slows down and finally reaches stability. Therefore, active drugs can be loaded on the surface of the implantable device to effectively inhibit cell proliferation in the lesion, keep the lumen unobstructed, and achieve therapeutic effects, that is, when the implantable drug-loaded device is implanted in the hu...

AI Technical Summary

Problems solved by technology

However, if excessive zinc is released during zinc corrosion, it will kill smooth muscle cells, even endothelial cells and other normal tissue cells, and eventually lead to tissue ulceration or necrosis at the implant site

[0004] When the implantable drug-loaded device can release both zinc and drugs that inhibit the proliferation of vascular tissue, the zinc and the drug will work together on the vascular tissue, and synergistically produce the effect of inhibiting angiogenesis and intimal hyperplasia. It is easy to act too strong and produce toxicity, leading to adverse tissue reactions and even tissue necrosis

Images